News
-
-
-
COMMUNIQUÉ DE PRESSE
Salix Announces 2024 Gastrointestinal Health Scholars Program
Bausch Health Companies Inc. has announced the 2024 Salix Gastrointestinal Health Scholars Program, offering scholarships of up to $10,000 to 10 students with GI diseases. Applications open until May 6, 2024. Learn more at www.salix.com/scholarship -
COMMUNIQUÉ DE PRESSE
Bausch Health Announces Board Refreshment
Bausch Health Companies Inc. nominates two independent and diverse candidates, Christian A. Garcia and Frank D. Lee, for election to its Board of Directors. Russel C. Robertson and Thomas W. Ross, Sr. will retire from the Board, and the new nominees are expected to fill their roles. Bausch Health's 2024 Annual Meeting details will be included in the proxy statement -
COMMUNIQUÉ DE PRESSE
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
Bausch Health Companies Inc. (NYSE/TSX:BHC) will release Q4 and full-year 2023 financial results on Feb. 22, 2024, followed by a conference call and webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update -
COMMUNIQUÉ DE PRESSE
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
Bausch Health and Ortho Dermatologics announced the U.S. launch of CABTREO Topical Gel, the first once-daily triple-combination topical treatment for acne vulgaris, approved by the FDA based on Phase 3 studies showing significant reductions in lesions -
COMMUNIQUÉ DE PRESSE
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Bausch Health Companies Inc. and Solta Medical have announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA), marking a significant milestone for Solta Medical and opening up significant opportunities in the Chinese market. The approval represents a substantial achievement for the R&D and Regulatory Teams, signifying continued growth for the Thermage technology. The non-invasive treatment, which uses radiofrequency technology to tighten and improve the texture of the skin, has seen over two million treatments globally and is now set to continue its growth in China. The approval paves the way for delivering proven technology to the Chinese market and signifies a crucial breakthrough in the medical aesthetics market. -
COMMUNIQUÉ DE PRESSE
Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
Bausch Health Companies Inc. and Solta Medical announce the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA). This approval represents a significant breakthrough in one of the largest medical aesthetics markets, allowing the companies to continue the momentum of the growth of Thermage in China. The non-invasive treatment, Thermage, is a versatile and effective technology that can be used on all skin types and genders, delivering exceptional results for patients. For more information, visit www.bauschhealth.com and www.solta.com. -
COMMUNIQUÉ DE PRESSE
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals presented oral arguments at the U.S. Court of Appeals for the Federal Circuit regarding the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued following the oral arguments. The company continues to advocate for the safety of patients benefiting from XIFAXAN® (rifaximin) 550 mg tablets, indicated for hepatic encephalopathy recurrence and irritable bowel syndrome with diarrhea. Salix Pharmaceuticals focuses on the prevention and treatment of gastrointestinal diseases for over 30 years and markets its products to U.S. health care providers. On the other hand, Bausch Health Companies Inc. is a global diversified pharmaceutical company with a mission to improve people's lives through various health care products, primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The news release contains forward-looking statements about Bausch Health's future performance and the appeal with respect to intellectual property. The actual results are subject to certain risks and uncertainties. For more information, visit www.bauschhealth.com and connect with them on Twitter and LinkedIn. -
